| Literature DB >> 28553642 |
Paulo V M Steagall1, Bradley T Simon2, Francisco J Teixeira Neto3, Stelio P L Luna3.
Abstract
This review aims to report an update on drugs administered into the epidural space for anesthesia and analgesia in dogs, describing their potential advantages and disadvantages in the clinical setting. Databases searched include Pubmed, Google scholar, and CAB abstracts. Benefits of administering local anesthetics, opioids, and alpha2 agonists into the epidural space include the use of lower doses of general anesthetics (anesthetic "sparing" effect), perioperative analgesia, and reduced side effects associated with systemic administration of drugs. However, the potential for cardiorespiratory compromise, neurotoxicity, and other adverse effects should be considered when using the epidural route of administration. When these variables are considered, the epidural technique is useful as a complementary method of anesthesia for preventive and postoperative analgesia and/or as part of a balanced anesthesia technique.Entities:
Keywords: analgesia; anesthesia; canine; epidural; local anesthetics; opioids; pain
Year: 2017 PMID: 28553642 PMCID: PMC5427076 DOI: 10.3389/fvets.2017.00068
Source DB: PubMed Journal: Front Vet Sci ISSN: 2297-1769
Commonly used and recommended epidural anesthetics and analgesics in dogs.
| Drug | Dose (mg kg−1) | Final volume (mL kg−1) injected into the LS epidural space | Onset time (min) | Duration of analgesia (h) | Comments | Reference | |
|---|---|---|---|---|---|---|---|
| 2% Lidocaine with 1:200,000 epinephrine | 5.0 | 0.25 | 4–6 | 1 | Duration of motor blockade 60–120 min | ( | |
| 0.5% Bupivacaine | 0.5–1.0 | 0.2–0.25 | 5–15 | >2 | Duration of complete motor blockade and ataxia was 65 and 240 min, respectively. May be prolonged with 0.75% bupivacaine. Complete motor blockade may not be observed at 0.25% | ||
| 0.5% Levobupivacaine | 0.5–1.0 | 0.2 | 5–15 | 1–1.5 | Duration of complete motor blockade and ataxia was 30 and 180 min, respectively. Complete motor blockade may not be observed at 0.25% | ||
| 0.75% Ropivacaine | 1.65 | 0.22 | 7–15 | 1.5–2.5 | Duration of motor blockade 90–150 min | ||
| Morphine PF | 0.1 | 0.1 for abdominal and pelvic procedures; 0.25 for thoracic procedures | 45–90 | 12–24 for pelvic limb and abdominal procedures at 0.1 mL kg−1; 5–6 for thoractomy procedures at 0.25 mL kg−1 | Reduced minimum alveolar concentration (MAC) by 30% and minimized CV depression from inhalant. Potential for urinary retention and pruritus | ( | |
| Buprenorphine | 0.004 | 0.2 | <60 | Up to or greater than 24 | Reduced risk for urinary retention | ( | |
| Morphine PF and 0.5% bupivacaine | 0.1 and 0.5–1.0 | 0.22 | <15 | Up to 24 | 67% return to normal motor function within 8 h. Potential for urinary retention | ( | |
| Oxymorphone and 0.75% bupivacaine | 0.1 and 1.0 | 0.2 | <15 | Up to 24 | Decreases in heart rate. Transient hypotension. Systemic absorption of epidural oxymorphone is high | ( | |
| Buprenorphine and 0.5% bupivacaine | 0.004 and 1.0 | 0.2 | <30 | Up to 24 | Low incidence of urinary retention | ( | |
| Dexmedetomidine | 0.003–0.006 | 0.25 | <15 | Up to 4.5 | Dose-dependent MAC reduction up to 4.5 h. Bradycardia and elevated blood pressure may occur. Minimal effects on motor function | ( | |
| Dexmedetomidine and 0.5% bupivacaine | 0.004 and 1.0 | 0.22 | <15 | Up to 24 | Less urinary retention when compared to opioid epidurals | Prolonged motor blockade compared to local anesthetic and opioid epidurals | ( |